Optionality Beyond Allergy
SCV is a Versatile Vaccine Platform with Options for Broad Applications and Utility Across Multiple Global Market Segments. Potential for Multiple Shots-on-Goal.
Allergy
USD 34.42 B
CAGR 9.7%
Driven by increase prevalence, immunotherapy advances and unmet need
Infectious Diseases
USD 35-40 B
CAGR 7%
Infectious Disease History: Mpox/Smallpox, Chikungunya, COVID
Animal Health
USD 10B
CAGR 10.9%
Livestock vaccines drive market and underpinned by zoonotic disease control
Pandemic Preparedness
USD 18.3 B
Government Funding
Policy driven demand.
SCV Platform Technology Positioned for 100-day Readiness
The SCV Vaccine has Broad Utility
Combination Vaccines
Leveraging the capacity of SCV to accommodate a large antigen payload within its genome, the SCV Vaccine Platform can be used to generate a combination vaccine against two or more pathogens.
Vaccines with Hostile Antigens
Proprietary technology enables SCV Vaccines containing hostile, cytotoxic or unstable antigens to be constructed and manufactured without impacting quality or yield.
Vaccines with Multiple Immunogens
Leveraging the capacity of SCV to accommodate a large antigen payload within its genome, the SCV Vaccine Platform can be used to generate complex vaccines that can target multiple elements of a single pathogen.
Immune Modulation
SCV vaccines leverage the established safety and immunogenicity of vaccinia viral vectors to trigger a Th1 immune response, facilitating an immune response switch and inducing immune tolerance.
Gene Therapy / Delivery
SCV vaccines can be a versatile delivery vehicle for therapeutic gene products. High levels of transgene expression can be temporarily achieved without integration into the host genome or virus replication.
Positioned for Rapid Response to New and Emerging Infectious Disease
The SCV Vaccine Platform has been designed to deliver safe, versatile and scale-able vaccines and is being positioned for new vaccine readiness within 100 days of pandemic pathogen antigen identification – an alternative to mRNA technology.
However, unlike most other vaccine platforms the broad utility and platform “plug and play” functionality the SCV Vaccine Platform has the potential to address Disease X.
Pan-family eg. pan-filovirus, orthopox
Multi-strain eg. Universal flu
Multi-disease
Mpox Vaccine (SCV-SMPOX)
SCV-SMPOX, our vaccine targeting mpox disease, is being positioned to address the lack of vaccine supply options currently impacting the response to the African outbreak of Mpox, declared by the World Health Organisation as Public Health Emergency of International Concern.
Sementis’ MPOX vaccine (SCV-SMPOX) has been de-risked and is ready to accelerate into a Clinical Development Program.
SCV-SMPOX is positioned to demonstrate the capacity of the SCV Vaccine Platform for manufacturing at scale.
COVID Vaccine (SCV-SMN)
Current COVID-19 vaccines only target the spike protein of SARS-CoV-2, a part of the virus that mutates frequently. This means these vaccines need regular updates to stay effective against new variants. While the risk of another coronavirus-driven pandemic remains, there’s an urgent need for a vaccine that offers protection against a broader range of coronavirus family members (pan-coronavirus).
Sementis’ SCV-Spike-Membrane-Nucleocapsid vaccine (SCV-SMN) expresses multiple SARS-CoV-2 antigens (spike, membrane, nucleocapsid) in a singular vector. By targeting and including multiple conserved regions of the SARS-CoV2 virus, SCV-SMN could be positioned as a pan-coronavirus vaccine.
SCV-SMN demonstrates the capacity of the SCV Vaccine Platform for accommodating multiple antigens and unstable immunogens.
Chikungunya/Zika vaccine (SCV1002)
Diseases brought about by chikungunya virus and Zika virus have limited vaccine options. Sementis has developed a combination vaccine that can be used for prophylactic treatments of chikungunya and Zika virus diseases.
This prototype vaccine leverages the unique characteristic of SCV by including two different disease antigens in the same vector.
Single shot efficacy with a strong and sustained immune response has been demonstrated in NHP models.
SCV1002 demonstrates the utility of the SCV Vaccine Platform for combination vaccines against multiple diseases.